N@N

SANTA CLARA, Calif.--([ BUSINESS WIRE ])--Agilent Technologies Inc. (NYSE: A) today announced that it has entered into an exclusive supply agreement with LipoScience Inc. to provide nuclear magnetic resonance (NMR) components for LipoScienceas Vantera Clinical Analyzer. The analyzer is the first fully-automated NMR diagnostic platform designed specifically for the clinical laboratory and cleared by the U.S. Food and Drug Administration.

"We are extraordinarily pleased to join forces with LipoScience to provide key components for this leading-edge diagnostic platform"

The Vantera Clinical Analyzer combines proprietary signal-processing algorithms and NMR spectroscopic detection to identify and quantify concentrations of lipoproteins and, potentially, small-molecule metabolites.

aWe are extraordinarily pleased to join forces with LipoScience to provide key components for this leading-edge diagnostic platform,a said Nick Roelofs, president of Agilentas Life Sciences Group.

aLipoScience is pioneering a new field of personalized diagnostics based on NMR technology. Broadening access to our proprietary diagnostic tests is central to our vision of becoming a clinical standard of care. We value Agilentas NMR expertise and look forward to partnering with them in our efforts to decentralize our NMR clinical analyzer to leading clinical laboratories and academic centers of excellence,a added Richard O. Brajer, chief executive officer of LipoScience.

About Agilent NMR Spectroscopy Technology

Agilent offers a complete line of NMR and spectroscopy products for research and industrial applications. NMR is a technique utilized by scientific researchers for structure identification or verification and to obtain dynamic information. In 2010, Agilent entered the NMR business with the acquisition of Varian, maker of the worldas first NMR instrument, the Varian A-60, in 1961. For more information visit [ www.agilent.com/about/newsroom/lsca/background/2011/bg_nmr.pdf ].

About LipoScience

LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. Its first proprietary diagnostic test, the NMR LipoProfile test, measures the number of low-density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 8 million NMR LipoProfile tests have been ordered. LipoScienceas automated clinical analyzer, Vantera has recently been cleared by the FDA and will be placed with national and regional clinical laboratories. LipoScience is driving toward a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of metabolic and other diseases. For further information on LipoScience, visit [ www.liposcience.com ] and [ www.theparticletest.com ].

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the worldas premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The companyas 20,000 employees serve customers in more than 100 countries. Agilent had net revenues of $6.6 billion in fiscal 2011. Information about Agilent is available at [ www.agilent.com ]

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at [ www.agilent.com/go/news ].